Using a model based approach to inform dose escalation in a Ph I Study by combining emerging clinical and preclinical information:

An example in oncology

S.Y. Amy Cheung, James W.T. Yates, Peter Lawrence, Marcelo Marotti, Barry Davies, Paul Elvin, Christine Stephens, Paul Stockman and Andrew Foxley

Innovative medicines, AstraZeneca R&D, UK

PAGE meeting, Glasgow, UK 2013
Phase I in Oncology

Single and Multiple Ascending Dose

• **Primary:**
  - Safety
  - Tolerability

• **Secondary:**
  - Pharmacokinetics (PK)
  - Anti-tumour activity (Early Efficacy Signal)

• **Exploratory**
  - Pharmacodynamics (PD) and PoM Biomarkers

• **Oncology:** Compounds generally unsuitable for healthy volunteers and studies often enrol patients for whom all other standard therapies have failed

• Sets recommended dose and schedule for rest of program e.g. Phase II/III

• Understand PK-PD-Safety-Efficacy relationship for future trials

• A range of administration schedules may also be studied e.g. intermittent vs. continuous

• **Study design aim:** To escalate the dose in steps to identify Maximum Tolerated Dose (MTD) and a Recommended Dose (RD) for future studies which balances safety and efficacy (PD effect) -and vs. maximising the number of patients that receive a therapeutic dose.

• Multiple dose escalation methods available
Dose escalation methods (1)
Rule based/algorithmic approaches

Common approaches in oncology.

Main concept: a small group of patients is treated at a given dose and dependant on the observed number of dose-limiting toxicities (DLT), a decision based on pre-defined rules will be made:

- Study a further group of patients at the next dose
- Study more patients at the same dose
- Declare MTD

Examples:
- 3+3 other variants such as (2+4, 3+3+3) etc
- Rolling 6 (R6)
- Accelerated titration methods (ATM) – can be model based.
- Pharmacologically guided dose (PGD)

Dose escalation methods (2)
Model based approaches

Less common approach but increasing in use.
• Probability of DLT

Combines prior information of drug with observed current trial data to inform escalation decision.
Use minimally informative dose-response model

Bayesian adaptive design
- Modified Continual Reassessment Method (mCRM)
- Time to event continual reassessment method (TITECRM)
- Escalation with overdose control (EWOC)

Dose-toxicity curve

Target toxicity level
\[ P(d_i, a) = \alpha_i \exp(a) \]
\[ 0 < \alpha_i < \ldots \alpha_k < 1 \]
\[ P(d_i, a) = \frac{\exp(-3 + a \cdot d_i)}{1 + \exp(-3 + a \cdot d_i)} \]
\[ P(d_i, a) = \left( \frac{\exp(d_i)}{\exp(d_i) + \exp(-d_i)} \right)^a \]
\[ i = 1, \ldots k \]
Could a population model based approach be more suitable?  
Data integration and variability assessment

• The rule based approach lacks of understanding of all the data available.
• The common model based approach lacks exposure-response at a population level.
• Integration:

Emerging paradigm for efficacy – why not safety?

Hence the incorporation of:
• Preclinical modelling result/ information– enables model continuum
• Emerging trial data
• Population model based approach – allow understanding of underlying mechanism and relationship between exposure, target engagement and safety during escalation
AZD5363: pan – AKT inhibitor

- Orally bioavailable selective pan AKT inhibitor of Akt 1, 2 and 3
- Dose and time dependent modulation of biomarkers observed
- Pre-clinically: PKPD and efficacy linkage understood

![Diagram of signaling pathway involving RTK, PI3K, PTEN, AKT, m-TORC1, m-TORC2, FOX01, GSK3β, S6K, and 4EBP1 with labels Apoptosis, Metabolism, and Growth.]
Western study is a Single/ Multiple Ascending Dose Study

Intermittent dosing arms opened at the discretion of the investigators based on emerging safety and pre-clinical pharmacology/efficacy data

* A study with similar design conducted in Japanese patients is also part of the programme
Population PK analysis demonstrates similar pharmacokinetics in Western and Japanese patients.
Simulating missed dose management strategy

Early Population PK is used to guide trial design

Questions:
• Can you resume and complete 4 days of dosing after an interruption due to toxicity?
• Should you stop and start at the next cycle?

Based upon on the simulated upper exposure range:
• If only 1 day of dosing is missed, then it is acceptable to complete the 8 doses with a reduced washout period.
• If two days are missed then one can administer 6 doses on that cycle.
If more days are missed, then restart at the next cycle.

Completing 6 doses after interrupting 1st cycle, still provides adequate washout before 2nd cycle
Parameter estimates show continual learning about PK with early estimates representative of current estimates

Pre-clinical prior stabilised estimates in early phase

- Robustness of model is a function of data cleanliness not just quantity
- Data not as informative in early stages about peripheral compartment parameters
- NONMEM ADVAN4 TRANS4 parameterisation

Used for Prediction

![Graph showing parameter estimates](image-url)
AKT component of insulin dependent glucose uptake

Model developed using pre-clinical data

Akt required for translocation of glucose transporters from cytoplasmic to functional plasma membrane location, in response to insulin receptor activation. Akt phosphorylation of GSK3\(\beta\) relieves inhibition of glycogen synthase and co-ordinates glucose influx and glycogen storage.

Akt inhibition by AZD5363 results in increased plasma glucose (inhibition of Glut4 function) and increased plasma insulin (dynamic response to elevated plasma glucose).
Population modelling guides dose escalation
PK-glucose relationship extrapolated to higher doses

Simulation of medium effects (97.5% upper quantile shown below)

Blood sugar back to baseline during ‘off drug’ days
Study flow – Western and Japanese patients

Efficient escalation and exploration of schedules

Continuous schedule (n=64) bid dosing

- 80 mg, n=8, 0 DLT
- 160 mg, n=5, 0 DLT
- 240 mg, n=12, 0 DLT
- 400 mg, n=14, 3 DLT
- 600 mg, n=2, 2 DLT

DTL: Dose-limiting toxicity

Intermittent schedules (n=29) bid dosing

- 480 mg, n=11, 0 DLT
- 640 mg, n=6, 1 DLT
- 800 mg, n=6, 1 DLT

Data cut off: Feb 18 2013
Unvalidated data

Ref: Results of two Phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors. Udai Banerji, Malcolm Ranson, Jan HM Schellens, Taito Esaki, Emma Dean, Marcelo Marotti et al. AACR13 Clinical Trials Symposium: The PI3 Kinase Pathway: Biomarkers and Clinical Targeting 2013
Population PKPD approach to dose escalation is advantageous

Greater flexibility of models

Allow:
• Comparison of populations
• Extrapolation to alternative schedules
• Model based translation of pre-clinical learning
• Guide cohort dose level and schedule decisions

Further work:
• Formal analysis of quantity of data required at each dose escalation
• There will be continued learning about PK, PD, safety profiles
Acknowledgement

• We thank all patients and families

• Thanks to Martin Pass (AZ project leader), all members of the AZD5363 team), Michelle D Garrett (The institute of Cancer Research) and Andrew Hastie (AZ).

• Thanks to Andrew Hughes (AZ Early Clinical Development), Marc-Antoine Fabre and Peter McCormack (AZ Quantitative Clinical Pharmacology) for discussions.

• Thanks to our investigators:
  • Uda Banerji (The institute of Cancer Research and The Royal Marsden NHS Foundation Trust, UK)
  • Malcolm Ranson and Emma Dean (Christie Hospital NHS Trust, UK)
  • Jan HM Schellens and Ruud van der Noll (The Netherlands Cancer Institute, The Netherlands)
  • Taito Esaki (National Kyushu Cancer Center, Japan)
  • Andrea Zivi (The Royal Marsden NHS Foundation Trust, UK)
  • Kenji Tamura (National Center Hospital, Japan)

• We are also grateful to clinical research coordinators of the Clinical Trial Support Office and nurses of ward 11A at the National Cancer Center Hospital, Tokyo
• Experimental Cancer Medicine Centres and Cancer Research UK for infrastructural funding for UK Phase I sites
• Collaborators at the Institute of Cancer Research
• AZD5363 was discovered by AstraZeneca subsequent to collaboration with Astex Therapeutics (and its collaboration with the Institute of Cancer Research and Cancer Research Technology Ltd)
• Sponsored by AstraZeneca
Confidentiality Notice

This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 2 Kingdom Street, London, W2 6BD, UK, T: +44(0)20 7604 8000, F: +44 (0)20 7604 8151, www.astrazeneca.com